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Bioresorbable linear poly(ether-ester-urethane)s with different hydrophilic characteristics were 
synthesized from triblock copolymers of poly(ε-caprolactone)-poly(ethylene oxide)-poly(ε-caprolactone) 
(PCL-PEO) as macrodiols, and L-lysine diisocyanate (LDI) or hexamethylenediisocyanate (HDI) were 
used as the required diisocyanates. Macrodiols were obtained by ring-opening polymerization (ROP) 
of ε-caprolactone (CL). Polyurethanes were synthesized by the reaction of the triblock copolymers with 
LDI or HDI in solution using stannous 2-ethylhexanoate as catalyst. Polyurethane tablets were fabricated 
and investigated as prospective drug delivery systems. The effect of the PEO content on the polymers’ 
performance as drug carriers was evaluated. It was found that water provoked more swelling and erosion 
of polymers with higher contents of PEO. The hydrocortisone release profiles were analyzed using the 
Ritger-Peppas approximation. An anomalous release behaviour (values of n higher than 0.5) was found 
for most of the analyzed samples.
Uniterms: Bioresorbable polyurethanes. Drug delivery. Hydrocortisone. Macrodiol.
INTRODUCTION
Hydrocortisone ((11β) 11,17,21-trihydroxy-(11β)-
pregn-4-ene-3,20-dione) is a hydrophobic drug that is 
used for the treatment of certain types of cancer (leukemia, 
lymphoma, and multiple myelomas), allergies, and 
inflammation, as well as other diseases. Hydrocortisone 
is applied topically, orally or by intravenous injection. 
Nevertheless, long-term administration requires high 
doses of hydrocortisone, which induces side-effects such 
as peptic ulceration, hypokalemic alkalosis, and edema 
(Filipović-Grcĉić et al., 2000). To overcome theabove 
problems, a sustained release system should be designed 
to administer the drug.
Controlled drug delivery technology represents one 
of the most rapidly advancing areas in pharmacology. 
This technology requires biodegradable polymers that 
are metabolized or excreted by the body as non-toxic 
compounds. Such systems offer numerous advantages 
compared to conventional dosage forms, including reduced 
dosing requirements, improved efficacy, and reduced 
toxicity (Deng et al., 1999; Deng et al., 2001; Park, Kim, 
Kim, 2005; Mohamadnia et al., 2009). Controlled release 
can be achieved by using various devices, for example 
mechanical pumps, osmotic pumps, diffusion-controlled 
systems containing reservoirs, or matrix systems, and 
chemically controlled systems composed of biodegradable 
or non-biodegradable polymers, among others (Park, Kim, 
Kim, 2005).
Some of the biodegradable materials include: 
poly(ethylene oxide) (PEO), polyurethanes (PUs), and 
poly(ε-caprolactone) (PCL), among others, which can 
self-disperse in certain solvents and behave as a good 
solvent for one block and as a poor solvent for the 
other, which permits the formation of nonionic micelles 
(Abraham, Marcos-Fernández, Román, 2006). PUs, which 
are commonly made by reacting hydroxyl-terminated 
polyesters or polyethers with polyisocyanates, are 
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considered excellent biomedical materials based on their 
good chemical stability, mechanical flexibility and their 
excellent blood compatibility (Cherng et al., 2013). PEO, 
which is used as the hydrophilic block in the copolymers, 
has been widely used to improve the biocompatibility 
of materials that contact the blood (Storey, Wiggins, 
Puckett, 1994; Deng et al., 1999). PCL, used as the 
hydrophobic block, is a biodegradable and biocompatible 
polymer that has been used in various biomedical 
applications because of its excellent biocompatibility and 
degradability (Bogdanov et al., 1999). Some authors have 
reported the use of PUs-based tablets containing 7-tert-
butyldimethylsilyl-10-hydroxy-camptothecin (Sivak 
et al., 2008), anhydrous theophylline (Campiñez et al., 
2013), diprophylline (Claeyes et al., 2014), and metformin 
hydrochloride (Verstraete et al., 2016). These studies 
suggested that PUs increases drug release.
This study reports the synthesis of PUs with different 
contents (30 and 40 mol%) and molecular weight (900 and 
2000 g·mol-1) of PEO. Tablets based on PEO-containing 
PUs were filled with hydrocortisone (1% w/w), mixed in 
solution, and molded from the soluble form and tested for 
drug delivery. In vitro matrix water uptake profiles were 
obtained by measuring the tablets’ weight increase. The in 
vitro hydrocortisone release profiles from the polyurethane 
tablets were also investigated. The results are discussed 
in terms of the PEO content. To our knowledge, there are 
no reports regarding the performance of amino acid-based 
polyurethanes as drug delivery carriers.
MATERIAL AND METHODS
Chemicals and reagents
Hexamethylene-diisocyanate (HDI), stannous 
2-ethylhexanoate, and 1,2- dichloroethane (DCE) were 
obtained from Sigma-Aldrich (St. Louis, MO). PEO diols 
(Sigma-Aldrich) with number-average molecular weights 
(Mn) of 900 and 2000 g·mol-1 were dried under vacuum at 
90 ºC for at least 6 h on a rotary evaporator before use. 
DCE was distilled over phosphorous pentoxide before 
its use. ε-Caprolactone (ε-CL) was obtained from Merck 
(Schuchardt, Germany) and used as received. L-Lysine-
diisocyanate (methyl 2,6-diisocyanatohexanoate)(LDI) 
was donated by Kyowa Hakko Co. Ltd, Japan.
Synthesis of poly(ester-ether-ester) macrodiols
Triblock copolymers (PCL-PEO-PCL) with different 
hydrophilic-to-hydrophobic ratios were synthesized 
by using the following procedure (Cerrai et al., 1994): 
ε-CL and the corresponding amount of PEO were placed 
into a three-necked flask. Stannous 2-ethylhexanoate 
(0.1% weight with respect to the monomer) was added. 
Polymerization was carried out in bulk for 2 h with 
magnetic stirring at 130 °C. The final product (macrodiol) 
was exhaustively dried under high vacuum (10-3 mm Hg) 
while cooling for 24 h at room temperature and stored 
under vacuum until used. All reaction yields were higher 
than 95%. 
Synthesis of poly(ether-ester-urethane)s (PEEUs)
To control the final molecular weight of the 
PEEUs, a nonstoichiometric monomer ratio was used 
(Li et al., 2009). The effect of stoichiometric imbalance 
on the final molecular weight was investigated in the 
polymerization reaction between LDI and commercial 
PCL-diol (Mn=1250). A catalyst concentration of 0.2% 
w/w was used. It was determined that the diisocyanate/
macrodiol molar ratio that produced the highest final 
molecular weight was 1.05:1. To obtain the PEEUs, 
polymerization was performed in DCE solution by mixing 
the diisocyanate and the macrodiol in 1.05:1 molar ratio at 
85°C with magnetic stirring under a nitrogen atmosphere 
for two hours. The molar concentration (0.39M) was 
selected to have less than 100% total w/v (polymer/
solvent). The resulting polymer was exhaustively dried 
under vacuum for complete solvent removal. 
Characterization
Proton nuclear magnetic resonance (1H NMR) 
spectra were acquired using a Varian XLR-300 NMR 
spectrometer operating at 300 MHz. The 1H NMR spectra 
were obtained from 5% w/v CDCl3 solutions at room 
temperature. The spectra were referenced to the residual 
solvent protons at δ 7.26 for CDCl3.
Differential scanning calorimetry (DSC) experiments 
were carried out in a Mettler Toledo (DSC822e) calorimeter 
under nitrogen purge. Samples weighing between 5 and 
15 mg were sealed in aluminum pans. Two scans were 
performed using a 10 °C min-1 heating rate, the first from 
ambient temperature to 80 ºC and the second from -90 
ºC to 80ºC. In both cases, the fastest cooling rate of the 
instrument was used between runs. 
The gel permeation chromatography-multi angle 
light scattering (GPC-MALLS) spectra were determined 
with a MALLS Dawn Eos F laser photometer using the 
ASTRA v 4.70 software (Wyatt Technology Corp., Santa 
Barbara, CA). A laser wavelength of 690 nm was used. 
For the analysis, a set of TSK Gel G 3000 HHR and G 
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6000 HHR columns were employed, and THF was used 
as eluent.
Preparation of PUs tablets
The PUs were placed in molds, melted at 60 °C, and 
solidified in a freezer to yield tablets of 7 mm diameter and 
1.5 mm thickness. Their final weights were in the range 
of 45 to 55 mg. 
Tablets containing 1% hydrocortisone (w/w) 
preparation
PUs were mixed with an acetone solution containing 
1% (w/w) hydrocortisone, and the solution was dried at 
60 °C under vacuum. The molten solids were placed in a 
mold and solidified in a freezer to yield tablets of 7 mm 
diameter and 1.5 mm thickness. Their final weights were 
in the range of 45 to 55 mg. 
In vitro release studies
The release of hydrocortisone was evaluated using 
UV-vis spectroscopy (Orozco-Castellanos, Marcos-
Fernández, Martínez-Richa, 2009). Tablets of un-filled and 
filled PUs were placed in vials with 15 ml of 0.1 M aqueous 
citrate buffer at pH 5.0 or 0.1 M aqueous phosphate buffer 
at pH 7.4 (both containing 0.05% w/v sodium azide as a 
preserving agent) in an incubator at 37°C. Aliquots of 
the upper layer (3.0 ml) were used for UV-vis analysis of 
the hydrocortisone concentration using an Agilent 8453 
UV–vis spectrophotometer (Agilent, Germany) at 248 nm. 
After analysis, the samples were returned to the original 
solution. Three runs were performed for each condition 
tested.
Swelling and erosion studies
The tablets (ranging from 40 to 60 mg) were 
immersed in 15 mL of phosphate buffer solution (pH 
7.4) at 37 °C. Thereafter, the tablets were removed from 
the solution at specific time intervals, wiped with filter 
paper, and then weighed immediately. The Water Uptake 
(WU) of the sample was calculated using the following 
expression (Abraham, Marcos-Fernández, Román, 2006; 
Dai et al., 2008): WU (%) = [(W - W0)/W0] × 100, where 
W is the weight of the swollen tablets and W0 is the initial 
weight of the tablets.
Erosion was evaluated 10 days after the start of the 
experiments. At that time, the tablets from the swelling 
study were removed from the falcon tubes, dried in an oven 
at 37±0.5 °C overnight, and then weighed after cooling to 
room temperature in a desiccator. The degree of erosion 
was calculated using the following formula (Caffagi et al., 
2005): Matrix erosion (%) = (W1-W3) / W1× 100, where 
W3 was the weight of dried slabs and W1 was the initial 
weight. The results are reported as the means of three 
determinations.
RESULTS
Synthesis and characterization of PEEUs
The list of the obtained polyurethanes can be 
found in Table I. The structure of the HO-PCL-b-PEO-
b-PCL-OH triblocks was characterized by 1H NMR. 
The methylene group adjacent to the hydroxyl terminal 
group (−CH2OH) for PCL appeared as a triplet at 3.62 
ppm, which completely overlapped with the signals 
attributed to the PEO main chain [−(CH2−CH2−O)n−]. 
To visualize the end-groups in the PCL block, hydroxyl 
terminal groups in HO-PCL-b-EO-b-PCL-OH were 
derivatized with trifluoroacetic anhydride (TFAA), which 
produced a trifluoroacetate end group (−CH2O(C=O)CF3), 
which produced a signal at 4.3 ppm that corroborated 
their chemical nature. The preparation of PEEUs was 
carried out by step-wise polymerization of HO-PCL-
b-EO-b-PCL-OH with L-lysine diisocyanate (LDI) or 
hexamethylenediisocyanate, (HDI) using Sn(Oct)2 as a 
catalyst. After the polymerization reaction, a series of 
PEEUs with different contents of PEO (TABLE I) were 
obtained (30-40 wt. %). 
The thermal properties in the PEEUs were studied 
using differential scanning calorimetry (DSC) (Table I). 
These results showed a series of endothermic peaks (Tm) 
that were mainly attributed to the fusion of PCL blocks 
in the PEEUs. 
Kinetics and mechanism of hydrocortisone 
release
The results of the hydrocortisone release study are 
reported in terms of percent hydrocortisone release and 
were calculated considering the entire time interval of the 
test, 0- 200 h. The release curves are shown in Figure 1.
The kinetics and the release mechanisms can be 
evaluated using the following equation (Ritger, Peppas, 
1987a,b; Cafaggi et al., 2005):
Mt /M∞ = k tn
where Mt /M∞ is the hydrocortisone fraction at time t, k 
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is a proportionality constant that accounts for the matrix 
characteristics, and n is an exponent whose value is 
indicative of the drug-release mechanism. The equation is 
valid only if data points covering up to 60% of the released 
hydrocortisone are considered. 
In a logarithmic representation, log k and n are 
obtained as the intercept and slope, respectively. The 
values of k and n obtained from the curves characteristic of 
the different matrices are reported in Table II. The results 
show that the n values varied from 0.55 to 0.78.
Swelling and erosion studies
Water uptake by the matrices and their erosion 
behavior can be evaluated from the curve profiles shown 
in Figure 2 and from gravimetric data, respectively. The 
PUs with a higher content of hydrophilic soft segments 
(polyethylene glycol, PEG) exhibited an increased water 
uptake as well as a faster degradation rate compared to the 
PUs with a higher content of hydrophobic soft segments 
(PCL) (Table III). 
In the hydrolytic stability study, weight-loss 
measurements were very difficult to achieve because the 
hydrophilic nature of the PEO segment precluded the 
complete drying of samples. At the end of the experiment, 
the 900-30 PUs lost between 1.8 and 4.0% of their initial 
weight, whereas the 2000-30 PUs degraded more slowly, 
retaining approximately 99.5% of their initial weight. The 
2000-40-Sn-LDI and the 2000-40-Sn-HDI PUs exhibited a 
higher weight loss (5.5 and 5.9%, respectively) (Table III). 
DISCUSSION
The macrodiols, which are precursors of the 
synthesis of PEEUs, are triblock copolymers derived from 
α,ω-hydroxytelechelic poly(ε-caprolactone-b-ethylene 
oxide-b-ε-caprolactone) (HO-PCL-b-PEO-b-PCL-OH) 
that obtained by ring-opening polymerization (ROP) of 
ε-caprolactone (CL) in presence of α,ω-hydroxytelechelic 
poly(ethylene oxide) (PEO) and tin octoate (Sn(Oct)2) as 
TABLE I - Number-average molecular weight (Mn), weight-average molecular weight (Mw) and thermal properties of the synthesized 
PEEUs
Polyurethane Mna Mwa PIa Tm (°C)b ΔHmc (J/g) xid
900-30-Sn-LDI 34610 41710 1.25 34, 41 44.6 32
900-30-Sn-HDI 45520 47580 1.04 37, 43 44.2 32
2000-30-Sn-HDI 35650 38050 1.06 44, 49, 61 67.3 49
2000-30-Sn-LDI 39100 60740 1.55 36, 42, 48 67.4 49
2000-40-Sn-LDI 34130 35290 1.03 21, 40, 45 66.6 49
2000-40-Sn-HDI 30770 39850 1.29 16, 42 61.9 45
a Obtained by GPC-MAALS; P.I. = Polydispersity index: Mw/Mn. b Obtained from the first heating scan by DSC. c Total area under 
the endothermic melting peaks. d Crystallinity (xi) of PCL in the PEEUs.
FIGURE 1 - Drug release (dissolution efficiency) curves from 
tablets of polyurethanes with 1% (w/w) hydrocortisone in 
phosphate buffer at pH 7.4 and 37 °C.
TABLE II - Values for k and n (± 95% confidence intervals) 
obtained by log plot of hydrocortisone release curves from 
tablets of different compositions at pH 7.4. R2 values are also 
reported
Matrix k n R2
900-30-Sn-LDI 0.042 0.759 0.985
900-30-Sn-HDI 0.080 0.789 0.996
2000-30-Sn-LDI 0.079 0.693 0.996
2000-30-Sn-HDI 0.057 0.731 0.994
2000-40-Sn-LDI 0.076 0.707 0.999
2000-40-Sn-HDI 0.139 0.551 0.999
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initiator and catalyst, respectively. Abraham, Marcos-
Fernández, Román (2006) reported that when the content 
of PCL (70-60 wt.%) is higher than the content of PEO 
(30-40 wt.%) the endothermic peaks can be attributed 
primarily to crystalline domains of PCL. The crystallinity 
(xi, Table I) was similar for PEEUs produced using either 
diisocyanate, LDI or HDI. Thus, the crystallinity was 
independent of the diisocyanate type. The number-average 
molecular weights (Mn) for PEEUs were obtained by GPC-
MALLS and demonstrated a range from 25000 to 39000 
Da. These values are convenient for the manufacture of 
PEEU films (Abraham, Marcos-Fernández, Román, 2006). 
In addition, the 1H NMR information obtained in this study 
corroborates the data from a previous study (Abraham, 
Marcos-Fernández, Román, 2006).
Using the criteria assumed for the evaluation of 
drug-release data from swelling systems (Ritger, Peppas, 
1987b), the calculated values for the prepared materials 
suggested that the release mechanism could be considered 
to be generally non-Fickian (Higuchi type of release) 
(Siepmann, Siepmann, 2012), although some the values 
were close to the Fickian limit of n = 0.5. Under these 
conditions, the hydrocortisone diffuses partially through 
the swollen matrix and partially through the hydrated 
expanding matrix. The mechanism for the release therefore 
became increasingly diffusion-mediated. This process 
is essentially as would be expected for a hydrophobic 
drug such as hydrocortisone, which is mainly entrapped 
in the hydrophobic-rich zones of the polymer. Based on 
the k values, which were generally moderate, the results 
indicated the presence of a moderate burst effect for all 
matrices. The release of drugs that are dispersed in (and 
not covalently bound to) PU matrices is dependent on the 
level of drug loading and the solubility of the drug in the 
matrix as well as the degradation rate and swelling of the 
matrices (Johnson et al. 2010). 
The swelling extent is represented by the maximum 
water uptake, as shown by the corresponding curves. For 
all the samples, the time to reach the steady-state or the 
water uptake was approximately 50 min. At longer times, 
the values remained almost constant for the next 8 hours. 
The results clearly show that the equilibrium values 
decrease with increasing PCL content. Therefore, materials 
with higher PEO content, which are more hydrophilic, are 
expected to display higher water contents at equilibrium. 
Thus, 2000-40-Sn-LDI and 900-30-Sn-HDI, which have 
different hydrophilicity, exhibited the highest and lowest 
water uptake values; 48.5 and 11.8%, respectively. 
As expected, there was a direct relationship between 
ethylene oxide (EO) unit content and water uptake. The 
2000-40-Sn-LDI and 2000-40-Sn-HDI samples exhibited 
a higher weight loss (5.5 and 5.9%, respectively). PUs 
are susceptible to biodegradation principally as the result 
of cleavage of hydrolytically sensitive bonds present in 
their soft segments. PUs with amorphous soft segments 
have been reported to degrade more rapidly than those 
with semi-crystalline soft segments (Skarja, Woodhouse, 
1998). Furthermore, a higher proportion of hard segments 
resulted in a lower rate of hydrolytic degradation because 
the crystallinity was higher than the water absorption 
(Campos et al., 2011). Moreover, an increase in the 
molecular weight of the PCL was associated with an 
increase in the crystallinity of the soft segments that in 
turn resulted in a decrease in the water uptake (Reddy 
TABLE III - Water uptake, erosion percent, and dissolution 
efficiency of polyurethane tablets
Polyurethane
Maximum 
water 
uptake (%)b
Matrix 
erosion 
(%)c
Dissolution 
efficiencya,b
900-30-Sn-LDI 17.1 1.83 53.4
900-30-Sn-HDI 11.8 4.08 49.8
2000-30-Sn-HDI 24.8 0.42 49.8
2000-30-Sn-LDI 24.0 0.46 62.1
2000-40-Sn-LDI 48.5 5.53 63.7
2000-40-Sn-HDI 47.0 5.90 51.0
aDefined as the area under the dissolution curve up to 192 h, 
expressed as a percentage of the area of the rectangle described 
by 100% dissolution in the same time. bn=3, pooled S.D. = 4.7 
(%). c n=3, pooled S.D. = 1.1(%)
FIGURE 2 - Swelling characteristics of dry slabs in phosphate 
buffer (pH 7.4) at 37 °C.
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et al., 2010). It was observed that the swelling rates 
for the samples studied herein increased with increases 
in the PEO content. The isocyanate moiety used (HDI 
or LDI) did not affect the swelling behavior. In other 
carriers for drug delivery, such as hydrophobic carriers 
that are used for hydrophobic drug delivery, it has been 
reported that the drug release might not be controlled by 
the carrier. Furthermore, some toxicity of these materials 
has been observed (Cabanes et al., 1998). In addition, the 
hydrophobic carriers used for hydrophobic drug delivery 
absorb less water and subsequently degrade more slowly 
(Makadia, Siegl, 2011). Therefore, polyurethane-based 
drug delivery could have some advantages compared to 
hydrophobic carriers. 
CONCLUSIONS
The observed release behavior indicated that the 
PEEUs studied in this paper have a potential use as 
delivery carriers for hydrophobic drugs. The 900-30 PUs 
were the best option for hydrocortisone delivery. Further 
studies are being carried out in our laboratory to provide 
a better characterization of hydrocortisone administration 
using these materials. 
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